 |
Indication & Dosage |
| |
| |
| Intravenous |
| SOLID TUMOURS OF THE BLADDER, BREAST, CERVIX, EYE, LIVER, LUNG, STOMACH AND PROSTATE |
| Adult:
Refer to published protocols. Suggested regimen: Initially, 10-20 mg/m2; may be repeated every 6-8 wk depending on blood count. Reduce dose depending on previous haematological response. Another suggested regimen is 2 mg/m2 daily for 5 days, repeated after 2 days. Adjust dose according to the effect on bone marrow. Do not repeat treatment unless leucocyte and platelet counts are above acceptable levels. Do not re-administer if the nadir of the leucocyte count is <2000 cells/mm3. Dose may need to be reduced when used with other antineoplastics. |
| |
| Intravesical |
| SUPERFICIAL BLADDER TUMOURS |
| Adult:
Instil 10-40 mg is instilled into the bladder 1-3 times a wk for a total of 20 doses. Doses are usually given in 10-40 ml of water for inj. Retain the solution in the bladder for at least 1 hr |
| |
| Intravesical |
| PREVENTION OF RECURRENT BLADDER TUMOURS |
| Adult:
Refer to published protocols. Suggested regimen: Initially, 10-20 mg/m2; may be repeated every 6-8 wk depending on blood count. Reduce dose depending on previous haematological response. Another suggested regimen is 2 mg/m2 daily for 5 days, repeated after 2 days. Adjust dose according to the effect on bone marrow. Do not repeat treatment unless leucocyte and platelet counts are above acceptable levels. Do not re-administer if the nadir of the leucocyte count is <2000 cells/mm3. Dose may need to be reduced when used with other antineoplastics. |
|
| |
|
| Precautions |
Repeated haematologic studies are necessary during treatment and for at least 7 wk after discontinuation of the drug. Discontinue use when the leucocyte count decreases to <4000/mm3 or the platelet count decreases to <150,000/mm3 or if a progressive decline in either occurs. Monitor patient for signs of renal or pulmonary toxicity. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
CHF; fever; alopecia, nail banding/discolouration; nausea, vomiting, anorexia; anaemia; rash; stomatitis; paraesthesia; increased creatinine; interstitial pneumonitis, infiltrates, dyspnoea, cough; malaise, pruritus, extravasation, bladder fibrosis/contraction (intravesical admin). |
| |
|
| Adverse Drug Reactions |
Myelosuppression, haemolytic-uraemic syndrome. |
| |
|
| Interactions |
Enhanced cardiac toxicity with doxorubicin. Increased risk of haemolytic-uraemic syndrome with fluorouracil or tamoxifen. Acute pulmonary toxicity may occur with vinca alkaloids. Increased bone marrow depressant effects of aclarubicin. |
| |
|
|
|
